Published • loading... • Updated
GSK to Halt Further Development of Cough Drug After Missing Main Goal
GSK said the drug’s limited benefit is unlikely to transform care after one 50 mg dose worked in only one of two studies.
- On Friday, GSK announced it will halt development of Camlipixant after the experimental drug failed to meet primary efficacy goals across two Phase 3 trials, sending shares down about 4%.
- The decision follows inconsistent data from CALM-1 and CALM-2 trials, where the 50mg dose reduced cough frequency in one study but failed in the second, while the 25mg dose missed efficacy targets in both.
- GSK acquired Camlipixant in a $2 billion deal three years ago through Bellus Health; the failure now complicates efforts to close the gap between analyst forecasts and the company's $40 billion revenue target.
- Shares of Trevi Therapeutics rose 16% on Friday as the failure removes a competitor; Leerink Partners analyst Roanna Ruiz noted this creates an "open field opportunity" for the company's treatment, Haduvio.
- GSK will continue testing Camlipixant for irritable bowel syndrome while shifting focus to its oncology portfolio, and the company plans to submit trial data for publication to aid future scientific research.
Insights by Ground AI
12 Articles
12 Articles
GSK stops development of chronic cough drug after late-stage trial miss
·London, United Kingdom
Read Full Article
According to mixed study results, GSK PLc ends the development of the medicine Camlipixant against chronic cough. Investors react disappointed, the share loses significantly in value.
·Düsseldorf, Germany
Read Full Article
GlaxoSmithKline Stops Work on Drug for Chronic Cough After Underwhelming Trial Results
GlaxoSmithKline on July 17 said it was halting development of a drug that was aimed at treating chronic cough. The company, known as GSK, ran two phase three clinical trials evaluating the drug camlipixant. In one trial, recipients taking 50 milligrams of camlipixant twice daily had statistically significant reductions in 24-hour cough at week 12 compared to placebo recipients, GSK said. In the other trial, there was no statistically significant…
·New York, United States
Read Full Article
Coverage Details
Total News Sources12
Leaning Left1Leaning Right3Center6Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
C 60%
R 30%
Factuality
To view factuality data please Upgrade to Premium
